Can-Fite BioPharma Ltd. (CANF)
| Market Cap | 7.30M -48.6% |
| Revenue (ttm) | 405,000 -39.9% |
| Net Income | -9.83M |
| EPS | -5.97 |
| Shares Out | 4.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,211 |
| Open | 3.380 |
| Previous Close | 3.370 |
| Day's Range | 3.310 - 3.400 |
| 52-Week Range | 2.560 - 13.400 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 2, 2026 |
About CANF
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat... [Read more]
Financial Performance
In 2025, Can-Fite BioPharma's revenue was $405,000, a decrease of -39.91% compared to the previous year's $674,000. Losses were -$9.83 million, 24.7% more than in 2024.
Financial StatementsNews
Can-Fite BioPharma files $100M mixed securities shelf
16:17 EDT Can-Fite BioPharma (CANF) files $100M mixed securities shelf
Can-Fite BioPharma Registration statement: Registration filing
Can-Fite BioPharma filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE ...
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- C...
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
Can-Fite BioPharma (CANF) announced the submission of a Phase 2 clinical study protocol to Bambino Gesu Children’s Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patient...
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWS...
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months
Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment
Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
Can-Fite BioPharma (CANF) announced that the Australian Patent Office has allowed Patent Application No. 2021290439 entitled “Treatment of Advanced Metastatic Cancer.” The patent complements Can-Fite’...
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molec...
Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study
Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
Can-Fite BioPharma (CANF) announced completion of enrolment of the first 247 patients in its Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. The study h...
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stag...
CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8
CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8
Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Can-Fite BioPharma (CANF) to $8 from $5 and keeps a Buy rating on the shares. The company reported “encouraging” Phase 2a data…
Can-Fite BioPharma (CANF) Reports Positive Results in Namodenoson Study
Can-Fite BioPharma (CANF) Reports Positive Results in Namodenoson Study
Can-Fite's Namodenoson Shows Survival Benefits In Pancreatic Cancer; Stock Jumps Pre-Market
(RTTNews) - Can-Fite BioPharma Ltd. (CANF) reported that its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and demonstrated encouraging sur...
Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint
Can-Fite BioPharma (CANF) announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated dura...
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ra...
Can-Fite BioPharma (CANF) Secures Key Patent for Fat Loss Treatment
Can-Fite BioPharma (CANF) Secures Key Patent for Fat Loss Treatment
Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists
Can-Fite BioPharma (CANF) announced that the Japan Patent Office has allowed Japanese Patent Application No. 2025-049941, a divisional application of JP 2023-078136, titled “An A3 Adenosine Receptor L...
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that a...
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (T...
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism
Growing momentum for RAS inhibition at ASCO highlights Namodenoson's RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioP...